Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
The Oncology Institute Inc (TOIIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/20/2025: TOIIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -88.15% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/20/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 12105 | Beta 0.43 | 52 Weeks Range 0.01 - 0.25 | Updated Date 03/29/2025 |
52 Weeks Range 0.01 - 0.25 | Updated Date 03/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -602.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -16.44% | Operating Margin (TTM) -11.9% |
Management Effectiveness
Return on Assets (TTM) -19.67% | Return on Equity (TTM) -213.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 46792770 |
Shares Outstanding - | Shares Floating 46792770 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
The Oncology Institute Inc
Company Overview
History and Background
The Oncology Institute, Inc. (TOI) was founded to improve access to cancer care in community settings. They focus on comprehensive, value-based cancer care and are known for their integrated model.
Core Business Areas
- Cancer Care Services: Provides a range of oncology services, including medical oncology, radiation oncology, and hematology.
- Value-Based Care: Focuses on delivering high-quality, cost-effective cancer care through risk-sharing arrangements.
- Care Management: Offers personalized care management programs to support patients throughout their cancer journey.
- Clinical Trials: Participates in clinical trials to advance cancer treatment options.
Leadership and Structure
The company is led by a team of experienced healthcare executives and physicians. The organizational structure includes clinical operations, finance, and business development divisions.
Top Products and Market Share
Key Offerings
- Market Share: Not Publicly Available
- Medical Oncology Services: Provision of chemotherapy, immunotherapy, and targeted therapies. Market share data is not publicly available at the product level, however, TOI serves a significant patient population within its geographic footprint. Competitors include large hospital systems and other independent oncology practices.
- Market Share: Not Publicly Available
- Radiation Oncology Services: Delivery of radiation therapy for cancer treatment. Market share data is not publicly available at the product level, however, TOI serves a significant patient population within its geographic footprint. Competitors include large hospital systems and other independent oncology practices.
- Hematology Services: Diagnosis and treatment of blood disorders and cancers. Market share data is not publicly available at the product level, however, TOI serves a significant patient population within its geographic footprint. Competitors include large hospital systems and other independent hematology practices.
- Market Share: Not Publicly Available
Market Dynamics
Industry Overview
The oncology market is experiencing growth due to the rising incidence of cancer and advancements in treatment options. The industry is competitive, with increasing consolidation and a shift towards value-based care models.
Positioning
TOI positions itself as a leader in community-based, value-driven cancer care. Its competitive advantages include its integrated care model, risk-sharing arrangements, and focus on patient experience.
Total Addressable Market (TAM)
The total addressable market is the overall cancer care market in the US, valued at hundreds of billions of dollars annually. TOI is positioned to capture a share of this market through its expansion strategy and value-based care approach.
Upturn SWOT Analysis
Strengths
- Integrated care model
- Value-based care expertise
- Strong relationships with payers
- Experienced management team
Weaknesses
- Limited geographic footprint
- Reliance on key personnel
- Lower Revenue vs other oncology companies
- Challenges in scaling operations
Opportunities
- Expansion into new markets
- Partnerships with other healthcare providers
- Increased adoption of value-based care models
- Growth in cancer incidence
Threats
- Increased competition
- Changes in healthcare regulations
- Reimbursement pressures
- Economic downturn
Competitors and Market Share
Key Competitors
- USON
- MOHO
- ACOR
Competitive Landscape
TOI's competitive advantage lies in its value-based care model and integrated services. Disadvantages include its smaller size and limited geographic reach compared to larger competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth would be assessed by analyzing revenue growth, patient volume, and geographic expansion over past years.
Future Projections: Future growth depends on analyst estimates, which typically factor in market trends, company strategy, and financial performance.
Recent Initiatives: Recent initiatives might include acquisitions, partnerships, new service offerings, and geographic expansion.
Summary
The Oncology Institute Inc. is focused on providing high-quality, community-based cancer care, but currently faces significant challenges and has been showing negative growth. Its strengths lie in its integrated model and value-based approach and will need to expand its footprint and manage competition to be sustainable. Investors should closely monitor the company's financial performance and strategic initiatives.
Similar Companies
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Third party financial data providers
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not investment advice. Market share data is based on estimations, due to unavailable granularity from primary source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About The Oncology Institute Inc
Exchange NASDAQ | Headquaters Cerritos, CA, United States | ||
IPO Launch date 2020-06-04 | CEO & Executive Director Dr. Daniel Virnich FACHE, M.B.A., M.D. | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 825 | Website https://theoncologyinstitute.com |
Full time employees 825 | Website https://theoncologyinstitute.com | ||
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.